Table 1.
Characteristics of patients in the minocycline and control groups.
| Variable | Minocycline group (n = 12) | Control group (n = 9) | P value |
|---|---|---|---|
| Demographic parameters | |||
| Age, years (median, IQR) | 54.0 (51.0–58.3) | 67.0 (64.0–72.0) | 0.012* |
| ≥65 (n, %) | 2 (16.7%) | 6 (66.7%) | |
| <65 (n, %) | 10 (83.3%) | 3 (33.3%) | 0.032* |
| Sex (male, n, %) | 7 (58.3%) | 5 (55.6%) | 1.000 |
| Body mass index, kg/m2 (median, IQR) | 22.8 (21.6–24.3) | 25.0 (23.2–27.4) | 0.079 |
| Clinical parameters | |||
| Highest temperature, °C (median, IQR) | 38.3 (37.5–38.6) | 38.3 (38.0–38.8) | 0.950 |
| Heart rate, beats/min (median, IQR) | 81 (73–93) | 75 (72–96) | 0.910 |
| Respiratory rate, breaths/min (median, IQR) | 15 (14–18) | 16 (13–19) | 0.654 |
| Systolic blood pressure, mmHg (median, IQR) | 120 (109–129) | 124 (120–130) | 0.403 |
| Oxygen support (n, %) | 1 (8.3%) | 2 (22.2%) | 0.553 |
| Duration from first symptoms to diagnosis, days (median, IQR) | 5.0 (3.5–5.0) | 3.0 (1.0–4.3) | 0.161 |
| Duration from first symptoms to admission, days (median, IQR) | 6.0 (3.5–7.0) | 4.0 (1.8–6.0) | 0.182 |
| Underlying diseases (n, %) | 6 (50.0%) | 6 (66.7%) | 0.661 |
| Cardiovascular disease (n, %) | 4 (33.3%) | 5 (55.6%) | 0.396 |
| Diabetes mellitus (n, %) | 1 (8.3%) | 4 (44.4%) | 0.119 |
| Endocrine disease (n, %) | 3 (25.0%) | 0 | 0.229 |
| Chronic kidney disease (n, %) | 0 | 0 | |
| Chronic obstructive pulmonary disease (n, %) | 0 | 0 | |
| Cancer (n, %) | 0 | 0 | |
| Chest imaging findings, infiltrate and/or ground-glass opacity (n, %) | 11 (91.7%) | 9 (100.0%) | 1.000 |
| Treatment | |||
| Duration from first symptoms to therapy†, days (median, IQR) | 8.5 (6.8–9.3) | 4.5 (1.8–7.0) | 0.010* |
| Duration of favipiravir administration, days (median, IQR) | 13.0 (10.0–14.0) | 11.0 (10.0–14.0) | 0.566 |
| Duration from admission to minocycline therapy, days (median, IQR) | 0 (0–0) | – | |
| Duration of minocycline administration, days (median, IQR) | 14.0 (12.8–15.3) | – | |
| Clinical outcomes | |||
| Duration of fever, days (median, IQR) | 2.0 (0–5.0) | 3.0 (2.0–5.0) | 0.903 |
| Duration from start of therapy† to viral RT-PCR negative result, days (median, IQR) | 14.0 (12.0–14.0) | 17.0 (15.0–20.0) | 0.017* |
| Hospital stay, days (median, IQR) | 19.0 (17.0–22.8) | 22.0 (19.0–32.0) | 0.120 |
| Mortality (n, %) | 0 | 0 | |
†Favipiravir with or without minocycline therapy.
*Values of P < 0.05 were deemed significant.
IQR, interquartile range.